Revealing vilazodone's binding mechanism underlying its partial agonism to the 5-HT1A receptor in the treatment of major depressive disorder-Reference-Cited by-同舟云学术

Revealing vilazodone's binding mechanism underlying its partial agonism to the 5-HT1A receptor in the treatment of major depressive disorder

Published:2017 Issue:42 Volume:19 Page:28885-28896
ISSN:1463-9076
Container-title:Physical Chemistry Chemical Physics
language:en
Short-container-title:Phys. Chem. Chem. Phys.

Author:

Zheng Guoxun¹²³⁴⁵,Xue Weiwei¹²³⁴⁵,Yang Fengyuan¹²³⁴⁵,Zhang Yang¹²³⁴⁵,Chen Yuzong⁶⁷⁸⁹¹⁰,Yao Xiaojun¹¹¹²¹³⁵,Zhu Feng¹²³⁴⁵^ORCID

Affiliation:

1. Innovative Drug Research and Bioinformatics Group

2. School of Pharmaceutical Sciences and Collaborative Innovation Center for Brain Science

3. Chongqing University

4. Chongqing 401331

5. China

6. Bioinformatics and Drug Design Group

7. Department of Pharmacy

8. National University of Singapore

9. Singapore 117543

10. Singapore

11. State Key Laboratory of Applied Organic Chemistry and Department of Chemistry

12. Lanzhou University

13. Lanzhou

Abstract

The binding mechanism of vilazodone to 5-HT_1A receptor was revealed via integrated computational methods. The identified binding mode will provide valuable information for medicinal chemists in designing and discovering novel SPARIs for MDD treatment.

Funder

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

Physical and Theoretical Chemistry,General Physics and Astronomy

Link

http://pubs.rsc.org/en/content/articlepdf/2017/CP/C7CP05688E

Reference103 articles.

1. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

2. Neuroimmune mechanisms of depression

3. Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information